AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor
Open Access
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 142 (3) , 973-976.e11
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Recombinant IgE antibody engineering to target EGFRCancer Immunology, Immunotherapy, 2012
- Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targetingMolecular Immunology, 2012
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and ImmunoescapeJournal of Clinical Oncology, 2010
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsCancer Immunology, Immunotherapy, 2008
- Establishment of a novel high-affinity IgE receptor-positive canine mast cell line with wild-type c-kit receptorsBiochemical and Biophysical Research Communications, 2008
- Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosisJournal of Immunological Methods, 2007
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Heterogeneity of polyclonal IgE characterized by differential charge, affinity to protein A, and antigenicity☆☆☆★★★Journal of Allergy and Clinical Immunology, 1997
- Immunohistochemical Examination of Light‐chain Expression (Λ/kRatio) in Canine, Feline, Equine, Bovine and Porcine Plasma CellsJournal of Veterinary Medicine Series A, 1996
- Differential binding properties of protein A and protein G for dog immunoglobulinsJournal of Immunological Methods, 1991